Compare CSX Corporation (CSX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs IDEXX Laboratories, Inc. — how do they compare? CSX Corporation trades at $47.28 (market cap $87.70B), while IDEXX Laboratories, Inc. trades at $518.98 (market cap $40.43B). The key difference: CSX Corporation is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and CSX Corporation pays a 1.18% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CSX | IDXX | |
|---|---|---|
Market Cap | $87.70B | $40.43B |
Volume | 6,980,781 | 692,164 |
Sector | Industrials | Health |
52-Week High | $53.21 | $766.68 |
52-Week Low | $33.68 | $504.70 |
Typical Hold Time | 55 Days | 46 Days |
Enterprise Value | $105.66B | $41.32B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.28, up 0.99% today, with a bullish technical signal and strong institutional interest. The railroad operator shows solid profitability with 22.2% net margins and 24.4% ROE, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analysts maintain a buy consensus with a $51 target, representing 8% upside. Recent news highlights upcoming Q3 earnings and institutional acquisitions.
CSX offers moderate upside potential with strong operational metrics offset by revenue pressures. Key opportunities include pricing power in freight rail and dividend growth, while risks involve economic sensitivity and competitive threats. The stock's premium valuation requires sustained execution to justify current levels.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
